Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Lymphocytic Leukemia Indolent B-cell Lymphomas Chronic Hepatitis B Lymphoma, Small Lymphocytic Mantle-Cell Lymphoma Waldenstrom's Macroglobulinaemia Follicular Lymphoma Adult patients between age of 18 years 2. Patients with indolent B-cell lymphoproliferative neoplasms that have relapsed or are refractory after at least one standard line of therapy that contains rituximab 3. Pathologically proven B-cell lymphoproliferative neoplasms including chronic lymphocytic leukaemia/small lymphocytic lymphoma, mantle cell lymphoma, marginal-zone B-cell lymphoma, and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma). 4. Pathologically proven follicular lymphoma, with relapse or disease progression > 12 months after previous rituximab therapy. 5. Chronic HBV carriers (HBsAg+) 6. Occult HBV carriers (HBsAg-, anti-HBc+ and HBV DNA-) 7. Haematology values within the following limits: 1. Absolute neutrophil count (ANC)1000/mm3 independent of growth factor support 2. Platelets 100,000/mm3, or 50,000/mm3 if bone marrow is involved, and independent of transfusion support in either situation 8. Biochemical values within the following limits: 1. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2 x upper limit of normal (ULN) 2. Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin 3. Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration Rate (Cockcroft Gault) ≥ 40 mL/min/1.73m2 9. Competent to give an informed consent  Concomitant chronic liver diseases not related to HBV 2. Known history of drug-induced liver injury, chronic active hepatitis C infection, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, on-going extra-hepatic obstruction caused by cholelithiasis, cirrhosis of the liver and portal hypertension 3. Known history of drug induced pneumonitis 4. Known history of inflammatory bowel disease 5. Woman who are pregnant or breast-feeding 6. Patients who do not consent to the use of effective contraception during the study 7. Active infections. 8. Evidence of ongoing active HBV hepatitis (ALT and/or AST > 2x upper limit of normal, and detectable HBV DNA) 9. Patients known to have histological transformation of CLL to an aggressive lymphoma 10. Vaccinated with live, attenuated vaccines within 4 weeks of enrolment